The federal Project Grant award "PRESERVING VISION AFTER NEUROTRAUMA (PREVANT)" was provided by the Defense Health Agency under CFDA Program 12.420 - Military Medical Research and Development. The $1,479,970.00 award to The Ohio State University, with a performance period from July 15, 2025 to July 14, 2029, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will focus on innovative...
The U.S. Defense Health Agency awarded a $1,489,045 project grant to The Ohio State University under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "PRESERVING VISION AFTER NEUROTRAUMA (PREVANT)", supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research aims to investigate medical solutions for battlefield and other neurotrauma-related vision impairments. This 4-year award,...
The Department of Defense's Defense Health Agency awarded a $1,158,179.00 Project Grant to The Ohio State University under the Military Medical Research and Development program (CFDA 12.420) to deliver a sustained therapeutic protein cocktail delivery system to prevent vision loss after ocular trauma. The project aims to develop innovative treatments for military service members and veterans by conducting basic, translational, and clinical research. As a sub-award under this grant, the...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,250.00 to The Ohio State University to conduct research on the use of MIF inhibition and glucocorticoid therapeutics as a synergistic treatment to promote neuronal survival in traumatic retinal injury. The research aims to develop novel therapies for this type of injury, which is of particular relevance to military personnel. The...
This $249,960 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The Ohio State University to investigate the effects of the aged inflammatory central nervous system (CNS) microenvironment on oligodendroglial properties and remyelination capacity. The research aims to advance scientific understanding of age-related changes in the CNS that can impact myelin repair, with potential applications for...
This federal Project Grant award for $7,700,740.00 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Ohio State University. The funding supports a 4-year research project titled "CONSEQUENCES OF BRAIN INJURY ON GLIA-NEURON DYNAMICS, NEUROPATHOLOGY, AND NEUROPSYCHIATRIC ILLNESS" aimed at investigating the effects of brain injury on glial-neuronal interactions, neuropathology, and neuropsychiatric conditions. The...
The Ohio State University received a $248,237 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund a 3-year project from July 1, 2023 to June 30, 2026 to research and address traumatic brain injuries among law enforcement officers. No additional details about specific products or services to be delivered under this award were provided. The Military Medical Research and Development program supports basic,...
The Defense Health Agency awarded a $512,751.00 Project Grant to The Ohio State University for the period from July 1, 2023 to June 30, 2026. The grant was provided under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the American public through innovative and impactful research, and to investigate medical solutions for the battlefield. The grant funds will...
The federal Project Grant award of $1,225,245.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research initiative titled "CARDIOVASCULAR RISK PROFILING OF DEPLOYMENT-RELATED RESPIRATORY DISEASE: A TRANSLATIONAL APPROACH" at The Ohio State University. The research project aims to investigate cardiovascular risk factors associated with deployment-related respiratory diseases, with the goal of developing...
This federal Project Grant award of $267,311 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports a randomized clinical trial utilizing crisis response planning for suicide prevention in military personnel with traumatic brain injury. The award was made to The Ohio State University, which will serve as the prime recipient, with a performance period from August 1, 2024 to July 31, 2027. The project aims to...